Day One Biopharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net Income Loss
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development assets
Share-based compensation expense
Depreciation expense
Accretion of discounts on short-term investments, net
Amortization of intangible assets
Amortization of operating right-of-use asset
Non-cash interest expense
Issuance of shares for research and development
Changes in derivative tranche liabilities
Loss from sale of property and equipment
Gain from sale of priority review voucher
Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Prepaid expenses and other current assets
Deposits and other long-term assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Operating lease liability
Other long-term liability
Net cash used in operating activities

Cash flows from investing activities:
Cash paid for purchase of short-term investments
Proceeds from maturity of short-term investments
Proceeds from sale of short-term investments
Cash paid for acquired intangible assets
Proceeds from Sale of Other Investments
Cash paid for acquired in-process research and development assets
Cash paid for purchase of property and equipment
Proceeds from sale of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred shares, net of issuance costs
Series A Preferred Stock
Series B Preferred Stock

Proceeds from issuance of convertible notes
Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs
Proceeds from issuance of prefunded warrants to purchase common stock in connection with private placement, net of issuance costs
Proceeds from issuance of common stock, net
Proceeds from issuance of common stock upon ESPP purchase
Proceeds from issuance of common stock upon stock option exercises
Proceeds from issuance of common stock upon Employee Stock Purchase Plan purchase
Cash provided by financing activities

Cash and Cash Equivalents, Period Increase (Decrease), Total
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosure of cash flow information:
Income taxes paid
Supplemental disclosures of noncash activities:
Cash not yet paid for acquired intangible asset
Right-of-use asset obtained in exchange for new operating lease liabilities
Recognition of contingent beneficial conversion feature upon notes conversion
Issuance of Series A redeemable convertible shares for research and development
Conversion of convertible notes and accrued interest into Series A redeemable convertible preferred shares
Issuance of derivative tranches liability
Transfers to redeemable convertible noncontrolling interest
Right of use asset capitalization
Exchange of 45,331,483 preferred, common, and incentive shares in connection with the Conversion (Note 1)
Exchange of redeemable convertible noncontrolling interest to 6,470,382 shares of common stock (Note 11)
Cash not yet paid for license agreement milestone payment

Comments